A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.
Non-small Cell Lung Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer|Metastatic Kidney Cancer|Cervical Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
DRUG: Zirabev
Safety profile, The following items that occurred from the baseline:

1. Adverse Events (AEs)
2. Serious Adverse Events (SAEs)
3. Expected Adverse Events (Expected AEs)
4. Unexpected Adverse Events (Unexpected AEs)
5. Adverse Drug Reactions (ADRs)
6. Serious Adverse Drug Reactions (SADRs)
7. Expected Adverse Drug Reactions (Expected ADR)
8. Unexpected Adverse Drug Reactions (Unexpected ADR), baseline up to approximately 4 years
Efficacy profile, OR CR SD PD

1. Non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

   • Four objective response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) (RECIST 1.1)
2. Glioblastoma multiforme patients • Four objective response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) (RANO-HGG), baseline up to approximately 4 years
This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.